Antibody-drug conjugate targeting protein tyrosine kinase 7, a receptor tyrosine kinase-like molecule involved in WNT and vascular endothelial growth factor signaling: effects on cancer stem cells, tumor microenvironment and whole-body homeostasis.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

17 citing papers in PubMed, 32 citations in OpenAlex.

1. Why Is Wnt/β-Catenin Not Yet Targeted in Routine Cancer Care?Pharmaceuticals (Basel, Switzerland) · 2024
   Review
2. Enzymatic Synthesis of Aptamer-Polynucleotide Nanoparticles with High Anticancer Drug Loading for Targeted Delivery.Biomacromolecules · 2024
   Article
3. PTK7: an underestimated contributor to human cancer.Frontiers in oncology · 2024
   Review
4. Intraglandular dissemination: a special pathological feature.Frontiers in oncology · 2024
   Review
5. A New Wave of Targeting 'Undruggable' Wnt Signaling for Cancer Therapy: Challenges and Opportunities.Cells · 2023
   Review
6. The peculiar challenge of bringing CAR-T cells into the brain: Perspectives in the clinical application to the treatment of pediatric central nervous system tumors.Frontiers in immunology · 2023
   Review
7. The clinical development of antibody-drug conjugates for non-small cell lung cancer therapy.Frontiers in immunology · 2023
   Review
8. Anti-PTK7 Monoclonal Antibodies Inhibit Angiogenesis by Suppressing PTK7 Function.Cancers · 2022
   Article
9. Fate decisions of breast cancer stem cells in cancer progression.Frontiers in oncology · 2022
   Review
10. New Era of Immunotherapy in Pediatric Brain Tumors: Chimeric Antigen Receptor T-Cell Therapy.International journal of molecular sciences · 2021
    Review
11. Cancer Stem Cell-Associated Pathways in the Metabolic Reprogramming of Breast Cancer.International journal of molecular sciences · 2020
    Review
12. Antibody-Drug Conjugates in Thoracic Malignancies: Clinical Trials Reveal Both Promise and Challenges.Targeted oncology · 2020
    Review
13. CAR T Cell Therapy for Pediatric Brain Tumors.Frontiers in oncology · 2020
    Review
14. Targeting of DDR1 with antibody-drug conjugates has antitumor effects in a mouse model of colon carcinoma.Molecular oncology · 2019
    Article
15. The RTK Interactome: Overview and Perspective on RTK Heterointeractions.Chemical reviews · 2019
    Review
16. Targeting Receptor Kinases in Colorectal Cancer.Cancers · 2019
    Review
17. Effectiveness of Antibody-Drug Conjugate (ADC): Results of In Vitro and In Vivo Studies.Medical science monitor : international medical journal of experimental and clinical research · 2018
    Article

Corrections and comments

• Comment on
  A PTK7-targeted antibody-drug conjugate reduces tumor-initiating cells and induces sustained tumor regressions.2017

Authors and funding

1 author at 1 institution in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.